Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study †

2008156 citationsJournal Articlebronze Open Access

Authors

Rimonabant 20 mg over 2 years promoted clinically relevant and durable weight loss and improvements in cardiometabolic risk factors.

Published in: European Heart Journal

Volume 29, Issue 14, pp. 1761-1771

Field-Weighted Citation Impact: 19.93